These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 341668)
1. Immunobiology and clinical importance of the complement system of man. Spitzer RE Adv Pediatr; 1977; 24():43-101. PubMed ID: 341668 [No Abstract] [Full Text] [Related]
3. [Complement: physiopathology, pharmacology and clinical aspects]. Orrico A; Auteri A Ann Sclavo Collana Monogr; 1985; 2(1-2):3-146. PubMed ID: 3880494 [No Abstract] [Full Text] [Related]
4. The C3 nephritic factor (C3NeF) and the heat labile complement inactivator (HLCI) in chronic hypocomplementemic mesangioproliferative glomerulonephritis. Berthoux FC; Carpenter CB; Traeger J; Merrill JP Adv Nephrol Necker Hosp; 1974; 4():91-108. PubMed ID: 4220002 [No Abstract] [Full Text] [Related]
5. Nephritic factor, C3 splitting activity, C3 and factor B breakdown products in glomerular diseases. De Vecchi A; Montagnino G; Scalia P; Tarantino A Ric Clin Lab; 1980; 10(1):93-7. PubMed ID: 6781054 [No Abstract] [Full Text] [Related]
6. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis. Perrin LH; Lambert PH; Miescher PA J Clin Invest; 1975 Jul; 56(1):165-76. PubMed ID: 1141431 [TBL] [Abstract][Full Text] [Related]
7. Membrane regulators of complement activation and their aberrant expression in disease. Asghar SS Lab Invest; 1995 Mar; 72(3):254-71. PubMed ID: 7898046 [No Abstract] [Full Text] [Related]
8. Complement activation in semi-solid medium: Insolubilization of properdin and the third component of complement (C3) in agar gels. Ziegler JB; Watson L; Goodkofsky I; Alper CA; Lepow IH J Immunol; 1976 Jan; 116(1):75-9. PubMed ID: 812917 [TBL] [Abstract][Full Text] [Related]
9. The complement system of man. 4. Ruddy S; Gigli I; Austen KF N Engl J Med; 1972 Sep; 287(13):642-6. PubMed ID: 4561829 [No Abstract] [Full Text] [Related]
10. [General comments on complement]. Belisario A; Modiano A; Cipolla C; D'Antuono G G Clin Med; 1980 Mar; 61(3):169-76. PubMed ID: 7390090 [No Abstract] [Full Text] [Related]
11. Role of complement and complement regulatory proteins in glomerulonephritis. Quigg RJ Springer Semin Immunopathol; 2003 May; 24(4):395-410. PubMed ID: 12778335 [No Abstract] [Full Text] [Related]
12. Evidence for activation of the alternate pathway in glomerulonephritis. Michael AF; McLean RH Adv Nephrol Necker Hosp; 1974; 4():49-66. PubMed ID: 4219999 [No Abstract] [Full Text] [Related]
13. Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro. Mollnes TE; Ng YC; Peters DK; Lea T; Tschopp J; Harboe M Clin Exp Immunol; 1986 Jul; 65(1):73-9. PubMed ID: 3641694 [TBL] [Abstract][Full Text] [Related]
15. Clearances of complement components, C3 proactivator and other serum proteins in chronic membranoproliferative glomerulonephritis (CMPGN). Geiger H; Good RA; Day NK Clin Nephrol; 1975; 3(4):139-47. PubMed ID: 1149337 [TBL] [Abstract][Full Text] [Related]